This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Inhaled insulin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Inhaled insulin (1):

  • is available in the USA as a rapid acting insulin; studies in people with type 1 diabetes suggest rapid pharmacokinetics (1)
  • pilot study found evidence that compared with injectable rapid-acting insulin, supplemental doses of inhaled insulin taken based on postprandial glucose levels may improve blood glucose management without additional hypoglycemia or weight gain (1)
    • although results from a larger study are needed for confirmation

  • Exubera, an inhaled form of rapid acting insulin developed by Pfizer, became the first inhaled insulin product to be marketed in 2006 (2)
    • but poor sales led Pfizer to withdraw it in 2007
    • Afrezza developed by Mannkind, that uses a different technology (technosphere) was approved by the FDA in 2014
      • technosphere technology (2):
        • contains recombinant human insulin dissolved with powder (fumaryl diketopiperazine)
        • once inhaled, technosphere insulin is rapidly absorbed upon contact with lung surface
        • inhalable insulin is delivered with a thumb size inhaler with a rather increased dosing flexibility
        • both components, insulin and powder (fumaryl diketopiperazine) are almost completely cleared from the lungs of healthy individuals within 12 hours of inhalation. In contrast to Exubera (8-9%) only 0.3% of insulin of inhaled insulin remained in lungs after 12 hours
      • FDA approved Afrezza with a caution (Risk Evaluation and Mitigation Strategy) for a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza

Inhaled insulin is contraindicated in patients with

  • chronic lung disease, such as asthma and chronic obstructive pulmonary disease

Inhaled insulin is not recommended in patients who smoke or who recently stopped smoking

A review noted (2):

  • may develop an increase in serum antibody levels though not related to any significant clinical change
  • acute bronchospasm in patients with asthma and COPD
  • may cause hypoglycemia, cough and throat pain/irritation
  • significant decrease in Diffusing Capacity of Lungs for Carbon Monoxide (DLCO) relative to subcutaneous insulin
  • smoking appears to enhance insulin absorption

All patients require spirometry (forced expiratory volume in 1 s [FEV1]) testing to identify potential lung disease prior to and after starting inhaled insulin therapy

Reference:

  • ADA. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2021. Diabetes Care 2021;44(Suppl. 1):S111-S124
  • Mohanty RR, Das S. Inhaled Insulin - Current Direction of Insulin Research. J Clin Diagn Res. 2017;11(4):OE01-OE02. doi:10.7860/JCDR/2017/23626.9732

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.